ONCY

Oncolytics Biotech

0.5180 USD
-0.0160
3.00%
At close May 14, 4:00 PM EDT
After hours
0.5276
+0.0096
1.85%
1 day
-3.00%
5 days
1.57%
1 month
-12.20%
3 months
-32.48%
6 months
-48.71%
Year to date
-44.29%
1 year
-56.10%
5 years
-74.36%
10 years
-91.73%
 

About: Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.

Employees: 28

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

100% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 7

67% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 6

10% more capital invested

Capital invested by funds: $1.1M [Q3] → $1.21M (+$107K) [Q4]

10% more funds holding

Funds holding: 42 [Q3] → 46 (+4) [Q4]

0.15% more ownership

Funds ownership: 1.55% [Q3] → 1.71% (+0.15%) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$3
479%
upside
Avg. target
$4.33
737%
upside
High target
$5
865%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
Maxim Group
Jason McCarthy
19% 1-year accuracy
6 / 31 met price target
479%upside
$3
Buy
Maintained
10 Mar 2025
HC Wainwright & Co.
Patrick Trucchio
24% 1-year accuracy
43 / 177 met price target
865%upside
$5
Buy
Reiterated
10 Mar 2025
RBC Capital
Douglas Miehm
42% 1-year accuracy
10 / 24 met price target
865%upside
$5
Outperform
Maintained
10 Mar 2025

Financial journalist opinion

Based on 4 articles about ONCY published over the past 30 days

Neutral
Seeking Alpha
8 hours ago
Oncolytics Biotech Inc. (ONCY) Q1 2025 Earnings Call Transcript
Oncolytics Biotech Inc. (NASDAQ:ONCY ) Q1 2025 Results Conference Call May 14, 2025 4:30 PM ET Company Participants Jon Patton - Director of Investor Relations and Communications Wayne Pisano - Chair of Oncolytics' Board of Directors and Interim Chief Executive Officer Dr. Tom Heineman - Chief Medical Officer Christophe Degois - Vice President of Business Development Kirk Look - Chief Financial Officer Conference Call Participants Patrick Trucchio - H.C. Wainwright Michael Freeman - Raymond James Operator Good afternoon, and welcome to Oncolytics Biotech First Quarter Conference Call.
Oncolytics Biotech Inc. (ONCY) Q1 2025 Earnings Call Transcript
Neutral
PRNewsWire
11 hours ago
Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum
American Society of Clinical Oncology (ASCO) GI Symposium data underscores pelareorep's clinical benefit in anal and pancreatic cancers Pelareorep featured in Key Opinion Leader event on oncolytic immunotherapies in breast and pancreatic cancers Poster on pelareorep's stimulation of adaptive and innate immunity to be shared at ASCO Annual Meeting Conference call and webcast today at 4:30 p.m. ET to discuss Q1 results and clinical outlook SAN DIEGO, Calif.
Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum
Neutral
PRNewsWire
1 week ago
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
Conference call and webcast to take place on Wednesday, May 14, 2025, at 4:30 p.m. ET SAN DIEGO and CALGARY, AB , May 6, 2025 Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Wednesday, May 14, 2025, at 4:30 p.m.
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
Neutral
PRNewsWire
2 weeks ago
Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action
ASCO data expected to highlight how pelareorep activates immune responses in pancreatic cancer patients Ongoing updates support potential of pelareorep combination therapies in one of the deadliest and hardest-to-treat cancers SAN DIEGO and CALGARY, AB , April 24, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, will present new data from Cohort 1 of the GOBLET study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago May 30-June 3, 2025 demonstrating pelareorep's anti-tumor activity in pancreatic ductal adenocarcinoma (PDAC) - the most common form of pancreatic cancer characterized by its poor prognosis and limited treatment options. "Pelareorep continues to deliver encouraging results in pancreatic cancer, where few effective treatments exist," said Thomas Heineman, M.D.
Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action
Neutral
PRNewsWire
1 month ago
Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital
SAN DIEGO and CALGARY, AB , April 10, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, has entered into a share purchase agreement (SPA) with Alumni Capital LP (Alumni), an institutional investor. This partnership will provide Oncolytics with a flexible source of funding, enabling the Company to progress pelareorep toward key clinical milestones and minimize dilution to create and sustain shareholder value.
Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital
Neutral
PRNewsWire
1 month ago
Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers
SAN DIEGO and CALGARY, AB , April 10, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, was discussed by field-leading key opinion leaders (KOLs) during a recent event hosted by H.C. Wainwright.
Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers
Neutral
Seeking Alpha
2 months ago
Oncolytics Biotech Inc. (ONCY) Q4 2024 Earnings Call Transcript
Oncolytics Biotech Inc. (NASDAQ:ONCY ) Q4 2024 Results Conference Call March 7, 2025 8:30 AM ET Company Participants Jon Patton - Director of Investor Relations and Communications Wayne Pisano - Chairman of Oncotic's Board of Directors and Interim CEO Tom Heineman - Chief Medical Officer Kirk Look - Chief Financial Officer Christophe Degois - Vice President of Business Development Conference Call Participants Michael Freeman - Raymond James Luis Santos - H.C. Wainwright Operator Good morning, and welcome to Oncolytics Biotech's Fourth Quarter and Full Year 2024 conference call.
Oncolytics Biotech Inc. (ONCY) Q4 2024 Earnings Call Transcript
Neutral
PRNewsWire
2 months ago
Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024
BRACELET-1 results in HR+/HER2- metastatic breast cancer surpass expectations, providing meaningful data for a registration-enabling study Data from GOBLET in pancreatic and anal carcinoma support continued development of pelareorep in these indications, with combination studies ongoing Cash position of $15.9 million provides runway through critical milestones into third quarter 2025 Management hosting conference call and webcast this morning at 8:30 a.m. ET SAN DIEGO and CALGARY, AB , March 7, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today reported on highlights and financial results for Q4 and year-end 2024.
Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024
Negative
Zacks Investment Research
2 months ago
Oncolytics Biotech (ONCY) Loses -9.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Oncolytics Biotech (ONCY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Oncolytics Biotech (ONCY) Loses -9.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Neutral
PRNewsWire
2 months ago
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
Conference call and webcast to take place on Friday, March 7, 2025, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB , Feb. 25, 2025 /PRNewswire/ --  Oncolytics Biotech ®  Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Friday, March 7, 2025, at 8:30 a.m.
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
Charts implemented using Lightweight Charts™